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Abstract 
Background and Aims  
Human obesity is accepted as an important risk factor for development of MetS. Adiponectin 
is linked to central obesity and ADIPOQ variants are promising markers for understanding the 
genetic base of obesity-related disorders. We performed analyses of adiponectin 
concentrations and ADIPOQ variants and tested their associations with obesity and MetS in 
young subjects of Croatian origin.  
Methods 
Biochemical and anthropometric parameters of MetS were obtained for 149 unrelated 
subjects. Adiponectin levels were measured by ELISA assay. ADIPOQ -11391G>A and -
11377C>G were genotyped by real-time PCR. 
Results 
BMI and WC, TG and GLUC showed inverse correlation, whereas HDL-C showed a positive 
correlation with adiponectin concentrations. For central obesity, we found association with -
11377C>G and with -11391G>A polymorphisms. ADIPOQ -11377GG and  -11391GA 
significantly increased the risk for the development of central obesity (OR 5.57 and OR 3.37, 
respectively). Significant association was found between -11391A, -11377G allele and 
haplotype and increased TG. -11377C>G and -11391G>A variant were significantly 
associated with the incidence of MetS. C>G mutation at position -11377 significantly 
increased the risk of MetS development (OR=2.93). Compared with the -11391G 
homozygotes, the carriers of the A allele had the significantly increased risk for the 
development of MetS (OR=3.15). The test of overall association showed statistically 
significant correlation of MetS with -11377C>G and -11391G>A haplotypes (p=0.008).  
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Conclusion 
Analysis of adiponectin concentration and ADIPOQ -11391G>A and -11377C>G gene 
variants could be clinically meaningful for estimation of  MetS risk in young population. 
Key Words: obesity, metabolic syndrome, adiponectin, gene polymorphism, young 
population 
Abbreviations: MetS, metabolic syndrome; ADIPOQ, adiponectin gene; ELISA, enzyme-
linked immunosorbent assay; PCR, polymerase chain reaction; BMI, body mass index; WC, 
waist circumference; TG, triglycerides, GLUC, glucose; HDL-C, high-density lipoprotein 
cholesterol; SNP, single nucleotide polymorphism; OR, odds ratio. 
 
 
 
Introduction 
 
Overweight and obesity are some of the most complex clinical syndromes whose prevalence 
in the world has reached epidemic proportions in recent decades; these syndromes affect both 
children and adults (1). Obesity has been widely accepted as an important risk factor for 
development of certain syndromes and many chronic diseases. Body mass index (BMI) was 
most widely used obesity indicator, but it seems that the best measure is waist circumference 
(WC) because it estimates the amount of visceral adipose tissue which contributes most to the 
metabolic changes that occur in the obese. Visceral fat accumulation is associated not only 
with quantitative and qualitative changes in serum lipids and lipoproteins (2) but also with 
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dysregulation in the secretion of adipocytokines which participate in the development of the 
metabolic syndrome (MetS) (3). The increasing prevalence of obesity in the European Union 
and the USA is a major health concern, and it is also becoming worrying in Croatia (4) In 
Croatia, the prevalence of overweight, obesity and central obesity is estimated to be 38.11%, 
20.34% and 43.52%, respectively (5). The genetics of obesity is complex and involves 
interactions between genes, gene and environment, and gene and nutrition and behavioral 
factors (6). Genome-wide association studies (GWAS) have identified numerous obesity-
related loci but precise identification of correlation between DNA sequence variation in 
specific gene and obesity phenotypes has been difficult (7). More than 400 chromosomal 
regions that encompass gene variants have been found to be involved in weight regulation and 
development of obesity, and considerable emphasis has been focused on gene polymorphisms 
related to MetS (8).  
MetS is a combination of several factors and is recognized as an important risk factor for both 
cardiovascular disease (CVD) and type 2 diabetes (T2D). The core risk factors leading to 
MetS include i) independent risk factors (atherogenic dyslipidemia, elevated blood pressure 
and elevated plasma glucose), ii) emerging risk factors (e.g., prothrombotic and 
proinflammatory state) and iii) underlying risk factors (e.g., obesity and insulin resistance). 
Other factors that aggravate MetS include physical inactivity, advancing age, hormonal 
imbalance and genetic factors which can affect both the underlying causes and individual 
metabolic risk factors (9,10). Adiponectin is the most abundant adipose tissue-derived 
cytokine with anti-inflammatory and anti-atherogenic properties which was linked to central 
obesity and proposed as the major contributor to MetS in addition to insulin resistance (IR) 
and CVD (11-13). The role of adiponectin in energy metabolism has been confirmed by its 
reverse correlation with the adverse features of MetS (14). Moreover, serum adiponectin 
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concentrations are highly heritable and are linked to adiponectin gene (ADIPOQ) (15, 16), 
underlining the importance of studying ADIPOQ as one of the gene candidates of obesity and 
consequently MetS. The ADIPOQ gene is located on chromosome region 3q27 (17) with 
other susceptibility loci for risk factors of MetS (18), obesity, T2D and CVD (12). Also, 
pedigree-based analysis using a variance component linkage model demonstrated a 
quantitative trait locus on chromosome 3q27 that is strongly linked to MetS (19). Taking into 
consideration all the above, the association of adiponectin with MetS and its traits seems more 
likely.  
Two promoter single nucleotide polymorphisms (SNPs) at the ADIPOQ locus, the -
11391G>A and -11377C>G, have been shown to alter the plasma adiponectin concentration 
and abdominal obesity and consequently affect the risk of MetS, T2D and CVD (20,12). 
Although the importance of ADIPOQ gene variants for the development of obesity and MetS 
has been widely recognized, their clear contribution has not yet been fully understood. The 
results of association studies are conflicting due to differences in age and genetic or ethnic 
background of study populations (21). In recent years, attention has shifted from reliance on 
clinical events and focused on screening for preclinical symptoms of disease.  
This study aimed to perform analysis of the possible associations of the ADIPOQ gene 
variants with abdominal obesity and increased susceptibility to the development of MetS in 
young subjects of Croatian origin. 
 
Materials and Methods 
 
Study subjects 
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A total of 149 unrelated young subjects (65 male, 84 female) aged 20-33 (mean 26±3 years) 
were chosen during routine medical check-up. Exclusion criteria included known 
cardiovascular diseases, confirmed diabetes, endocrine disease, significant renal or hepatic 
disease and other chronic disease, use of medications that could alter blood pressure, glucose 
or lipid metabolism. The participants had their blood tests completed and anthropometric 
measurements taken. All participants signed informed consent forms, and the study protocol 
was approved by Ethics Committee of the University Hospital Centre Zagreb.  
Clinical and Biochemical Measurements  
Clinical and biochemical parameters were measured by standard laboratory procedures. The 
measurings of weight, height and WC were done in a standardized manner. The weights and 
heights of participants were measured while wearing light clothing and without shoes. Weight 
was measured to the nearest 0.1 kg on a medical balance scale. Height was measured to the 
nearest 0.1 cm with stadiometer. BMI was calculated as weight (kg)/height(m2). WC was 
measured twice to the nearest 0.5 and the mean was used for subsequent analyses. Overweight 
and obesity were defined as a BMI between 25.0 kg/m2 and 29.9 kg/m2, and ≥30 kg/m2, 
respectively, as proposed by WHO (22). Central obesity was defined as a WC≥94 cm for men 
and the WC≥80 cm for women according to the criteria of the International Diabetes 
Federation (IDF) (23). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 
calculated from two readings with a minimal interval of 5 minutes. Elevated blood pressure 
was defined according to IDF criteria by a SBP that was ≥ 135 mm Hg and a DBP that was ≥ 
85 mm Hg for men and women, respectively (23). Blood samples for serum biochemical 
analyses (total cholesterol (TC), triglycerides (TG), LDL-cholesterol (LDL-C), HDL-
cholesterol (HDL-C) and glucose (GLUC)) were collected after overnight fasting. Plasma 
concentrations of GLUC, TC and TG were measured by standard enzymatic methods (24) 
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with Olympus System Reagent 800 kit on an Olympus AU2700 autoanalyzer (Olympus, 
Tokyo, Japan). HDL-C was also determined enzymatically after precipitation of very low 
density lipoprotein (VLDL) and low density lipoprotein (LDL) by polyethylene glycol 
solutions (Quantolip Immuno AG, Vienna, Austria) and also measured on an Olympus 
AU2700. LDL-C was calculated using Friedewald Equation (25). If TG concentration was 
higher than 3.0 mmol/L, HDL-C was measured by direct immunoinhibition method (Olympus 
Diagnostica GmbH, Lismeehan, Ireland), and if TG concentrations were higher than 4.5 
mmol/L, LDL-C was measured by homogenous assay (Randox Laboratories, Crumlin, United 
Kingdom). Fasting plasma adiponectin concentration was determined using a validated 
sandwich enzyme-linked immunosorbent assay (ELISA kit, adiponectin: E09, Mediadiagnost, 
Reutlingen, Germany). The assay uses two specific and high affinity antibodies and 
determines total adiponectine in human serum and plasma samples. Blueher et al. (26) 
demonstrated that total adiponectine, as measured by Mediagnost test, is significantly 
correlated with insulin sensitivity and metabolic variables. Additionally, their study showed 
that total adiponectin, as measured by Mediagnost test, was clearly superior to HMW at 
identifying the presence of insulin resistance and predicting the levels of metabolic variables 
(26). The values of adiponectin were interpreted in relation to BMI and age of subjects. MetS 
was defined using the diagnostic criteria of the IDF (23). We used this definition, and not 
ATPIII definition, because central obesity is the key point in IDF definition. This point is 
further elaborated in a way that various reference intervals for waist circumference have been 
stated as valid for different ethnic groups. This approach enabled the application of this 
definition in different populations and at the global level. An individual with a combination of 
central obesity (defined as WC ≥ 94cm for European men and ≥ 80cm for European women) 
and any two or more of the following risk factors was classified as having MetS: elevated 
triglyceride levels (TG≥1.695 mmol/L), reduced HDL-C (HDL-C<1.036mmol/L for men and 
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<1.295 mmol/L for women), elevated blood pressure (SBP ≥ 130 mm Hg or DBP ≥ 85 mm 
Hg), and increased fasting plasma glucose (GLUC≥5.6 mmol/L.). Hypercholesterolemia  and 
increased LDL-C levels were identified when TC≥5 mmol/L and LDL-C>3.0 mmol/L were 
determined, respectively. 
 
ADIPOQ (-11391G>A and -11377C>G) genotyping 
 
Human DNA was extracted from leukocytes in whole blood samples, following the standard 
salting out method (27). DNA was amplified in a 20 µL reaction volume. The ADIPOQ gene 
promoter SNPs -11391G>A (rs17300539) and -11377C>G (rs266729) were genotyped by 
applying DNA assay that uses real-time PCR and fluorescence resonance energy transfer 
(FRET) with the LightCycler (Roche Diagnostics, Germany). Analyses for SNPs -11391G>A 
and -11377C>G were performed using primers and hybridization probes as previously 
described by Schwarz et al. (28). The reaction mixture for each PCR consisted of 100 ng of 
genomic DNA, 0.5 µl of each primer (0.125 µmol/L), 0.4 µl of each DNA hybridization probe 
(0.04 µmol/L), 2.0 µl DNA ''Fast start’’ mix, and 3.0 µl of MgCl2 (3.75 mmol/L). After initial 
denaturation at 94°C for 3 sec, 40 PCR cycles were performed with 1 s of denaturation at 
95°C; 14 s of annealing at 58°C and extending at 72°C for 10 s. Genotyping was carried out 
via melting curve analysis. Replicate quality control samples were included and genotyped 
with 100% concordance. 
 
Statistical analysis 
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SPSS 17.0 (SSPS Inc., Chicago, IL) and MedCalc 10.2.0.0. (Frank Schoonjans, Mariakerke, 
Belgium) were used for descriptive statistical analysis. The comparisons between the study 
groups were analyzed using Student’s t-test or Mann-Whitney test, depending on distribution 
normality or χ2 and Fischer exact test for categorical variables. Relationships between 
adiponectine and other variables were presented as Spearman’s rank correlation coefficients. 
The association of ADIPOQ -11377C>G and -11391G>A gene variants and haplotypes with 
the development of central obesity, MetS and their components was tested using program 
UNPHASED ver. 3.0.10. (29). A test for Hardy-Weinberg equilibrium using Markov chain 
method (30), as implemented in Arlequin ver. 3.01 (31) was applied. A linkage disequilibrium 
likehood-ratio test between loci was performed by Arlequin ver. 3.01 (31). The level of 
significance was set at p<0.05. 
Results 
Population sample description 
The clinical and metabolic characteristics of participants are shown in Table 1. 43.6% of the 
study population included men and 56.4% of the population was female. Eighty-eight (59.1%) 
young adults had normal weight, 37 (24.8%) were overweight and 24 (16.1%) were obese. 
Central obesity was found in 46,6% (39/84) of women and in 44,6% (29/65) of men. 
Hypertriglyceridemia and hypercholesterolemia were detected in 21.5% and 30.9% of 
subjects, respectively. Increased LDL-C was found in 32.2% of subjects. Decreased HDL-C 
was found in 4.8% (4/84) of women and in 12.3% (8/65) of men. Elevated SBP and DBP 
were detected in 15.4% and 19.5% of subjects, respectively. Increased fasting plasma glucose 
was detected in 4.0% of subjects.  
With the exception of BMI and adiponectin, there were no differences between sexes for the 
measured variables (data not shown). No differences in genotype distribution according to 
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gender were detected (data not shown). Therefore, all analyses were performed by including 
male and female subjects in the same group. Of 149 subjects, MetS was defined in 34 subjects 
(22.82%). All MetS variables (SBP, DBP, WC, HDL-C and GLUC) were significantly 
different in the MetS group as compared to the group without MetS. Moreover, the MetS 
group had significantly higher BMI, LDL-C and TC concentrations, and lower adiponectin 
level compared to the group without MetS (Table 1) The Mets variables (DBP, WC, HDL-C 
and GLUC) and LDL-C and TC were significantly different between the two groups even 
after adjustment for BMI (data not shown).  
 
Correlation of adiponectin concentrations with anthropometric and metabolic variables  
 
The levels of total adiponectin in serum ranged from 0.87 mg/L to 38.5 mg/L. The serum 
concentrations of adiponectin in women (13.9±8.2 mg/L) were significantly higher (p<0.001) 
that those in men (6.14±4.32 mg/L). As shown in Table 2, anthropometric parameters (BMI 
and WC) and the concentration of TG showed the strongest significant inverse correlation 
with adiponectin concentrations (p<0.001), whereas HDL-C showed a strong positive 
correlation with adiponectin concentrations (p<0.001). The concentration of GLUC also 
showed an inverse significant correlation with adiponectin (p=0.012), as well as SBP and 
DBP (p<0.001) (Table 2). The correlation between serum adiponectin level and TG, HDL-C, 
GLUC, SBP and DBP were significant even after adjustment for sex and anthropometric 
parameters (BMI and WC) (data not shown). 
 
Genetic analysis 
The allele frequencies of the two SNPs in the ADIPOQ gene were as follows: -11377C>G  
(C:G=0.68:0.32) and -11391G>A (G:A=0.79:0.21). The frequencies of the ADIPOQ -
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11377C>G variants CC, CG and GG were 68 (45.6%), 67 (45.0%) and 14 (9.4%), 
respectively.  The frequencies of the ADIPOQ -11391G>A variants GG, GA and AA were 89 
(59.7%), 57 (38.3%) and 3 (2.0%), respectively. There was no deviation from the expected 
proportions of genotypes in the population predicted by the Hardy–Weinberg equilibrium 
(ADIPOQ -11377C>G p=0.573, ADIPOQ -11391G>A p=0.133). Test results for linkage 
disequilibrium were found to be significant (r2 =0.1278, χ2=38.098, p<0.001) between the two 
loci. 
 
Association of ADIPOQ -11377C>G and -11391G>A polymorphisms with central obesity 
 
We compared the genotype distribution of SNPs of -11377C>G and -11391G>A of ADIPOQ 
in the group of subjects with central obesity (WC ≥94 cm for men; WC ≥ 80 cm for women) 
and in the group of subjects who did not meet the criteria for central obesity (WC <94 cm for 
men; WC<80 cm for women) to examine if the above SNPs were significantly related to 
central obesity (Table 3). The genotype distribution of ADIPOQ -11377C>G and -11391G>A  
was different between subjects with and those without central obesity (p=0.025 and p=0.002, 
respectively). In relation to central obesity, a significant association was found for the -
11377GG variant (16.1% vs. 3.7%,). The frequency of the -11377C and -11377G alleles was 
significantly different between the two groups (p=0.031), and the carriers of the -11377C 
allele were more frequent among the subjects who did not meet the criteria for central obesity 
(73.4% vs. 61.8%). The G allele and the GG genotype of the -11377 SNP significantly 
increased the risk for the development of central obesity [OR 1.71 (95%Cl 1.03-2.85), 
p=0.032 and OR 5.57 (95%Cl 1.42-21.82), p=0.014, respectively]. The -11377CC genotype 
decreased the odds ratio for the development of central obesity compared with G 
homozygotes [OR 0.17 (95%Cl 0.05-0.70), p=0.014]. The frequencies of the -11377CG 
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genotype were not different between the groups and the odds ratio was not significant. The 
frequency of -11391GG SNP was significantly lower among the subjects with central obesity 
(44.1% vs. 72.8%). The frequency of the –11391G and -11391A alleles was significantly 
different between the two groups (p=0.001) and the carriers of the -11391A allele were more 
frequent among the subjects with central obesity (29.4% vs. 14.2%). The A allele and the GA 
genotype of the -11391G>A SNP significantly increased the risk of central obesity [OR 2.52 
(95%Cl 1.34-4.72), p=0.002 and OR 3.37 (95%Cl 1.68-6.75), p<0.001, respectively]. No 
significant OR was established for the AA homozygotes at -11391 position since only two 
subjects in the group with central obesity and one in the group without central obesity were 
found. Each mutation of G>A allele at position -11391 significantly increased the odds ratio 
for central obesity [OR 3.40 (95%Cl 1.71-6.74), p<0.001].  
 
Associations of ADIPOQ -11377C>G and -11391G>A polymorphisms with metabolic 
parameters  
 
Analysis of association of ADIPOQ -11377C>G and -11391G>A with  hypertriglyceridemia 
is presented in Table 4. The genotype distributions at position -11391 were different between 
the groups of subjects with (TG≥1.695 mmol/L) and without (TG<1.695) (p=0.048). 
hypertriglyceridemia. Among subjects with hypertriglyceridemia, the frequency of -11391GG 
was lower compared to those without hypertriglyceridemia (43.8% vs. 64.2%), and mutation 
of G>A allele at position -11391 significantly increased the incidence of  
hypertriglyceridemia [OR 2.30 (95%Cl 1.04-5.08), p=0.04]. The frequency of the -11391G 
and 11391A alleles was significantly different between the two groups (p=0.025) and the 
carriers of the -11391A allele were more frequent among subjects with increased TG levels 
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(31.2% vs. 18.4%). We found no association of ADIPOQ -11377C>G variants with  
hypertriglyceridemia.  
Association between other analyzed parameters and -11377C>G and -11391G>A SNPs did 
not reach statistical significance.  
 
Associations of ADIPOQ -11377C>G and -11391G>A polymorphisms with MetS 
 
We compared the genotype distribution of ADIPOQ -11377C>G and -11391G>A in the group 
of subjects who met (MetS group) and the group who did not meet the criteria for MetS 
(control group) to examine if they were significantly related to MetS subjects. Distribution 
frequency of -11377C>G and -11391G>A ADIPOQ alleles and genotypes of the studied 
subjects are shown in Table 5. The ADIPOQ genotype distributions at positions -11377 and -
11391 were different between MetS and control subjects (p=0.031 and p=0.008, respectively). 
Among subjects with MetS, the frequency of -11377CC genotype was significantly lower 
compared to the subjects without MetS (26.5% vs. 51.3%). The subjects with -11377CG 
genotype had higher risk for development of MetS [OR 2.79, (95%Cl 1.16-6.69), p=0.013] 
than -11377CC genotype carriers (CC genotype vs. others, χ2=6.87, p=0.009). C>G mutation 
at position -11377 significantly increased the risk of MetS development [OR=2.93 (95%Cl 
1.26-6.81), p=0.013]. The frequency of the -11377C and -11377G alleles was significantly 
different between the two groups (p=0.015) and the carriers of the -11377G allele were more 
frequent in the MetS group (44.1% vs. 28.2%). The G allele at position -11377 significantly 
increased the risk of MetS [OR 2.00 (95%Cl 1.15-3.50), p=0.015]. 
The frequency of -11391GG genotype was lower among the subjects with MetS compared to 
the control subjects (38.2% vs.66.1%). The subjects with -11391GA genotype had higher risk 
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for the development of MetS [OR=2.92, (95%Cl 1.31-6.54), p=0.009] than the -11391GG 
genotype carriers (GG genotype vs. others, χ2=7.72, p=0.005). Compared with the -11391G 
homozygotes, the carriers of the A allele significantly increased the risk of MetS development 
[OR=3.15 (95%Cl 1.43-6.95), p=0.005]. The allele frequency at position -11391 was 
significantly different between the two groups (p=0.005) and the carriers of the -11391A 
allele were more frequent in the MetS group (33.8% vs. 17.4%). The A allele at position -
11391 significantly increased the risk for MetS [OR 2.43 (95%Cl 1.32-4.46), p=0.004]. 
 
Haplotype analysis  
 
Test of overall association showed statistically significant correlation of MetS with ADIPOQ -
11377C>G and -11391G>A haplotypes (χ2= 11.72; dF=3 p=0.008), with specific haplotype -
11377G-11391A having the strongest association (OR=4.09, 95%CI 1.61-10.41, p=0.001). 
Also, statistically different concentrations of triglycerides were observed according to 
different haplotypes (χ2= 10.34 dF=3 p=0.016), with -11377G-11391A haplotype contributing 
to the highest triglyceride levels (χ2 = 7.79, p=0.005).  
 
Discussion 
 
The goal of this study was to test the role of adiponectin level and gene variability as markers 
of abdominal obesity and MetS in a cohort of young adults of Croatian (Caucasian) origin. In 
this investigation, waist circumference was used as a valid marker of central obesity. Central 
obesity was detected in 46,6% of women and 44,6 % of men, which is similar to the data  
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described for the entire population of Croatian origin (5). The research of scale and dynamics 
of overweight and obesity epidemic in Croatia showed that in the recent years the age-
stratified prevalence of obesity showed the highest increase in a young group of adults (18-34 
years) (32), which is why we chose them as subjects in our study. The youngest adults should 
be treated as a priority population group that requires substantial public health intervention 
aimed to reduce the epidemic of obesity and obesity comorbidities. As a marker of central 
obesity, WC is one of the diagnostic criteria of MetS because subjects with central obesity 
have been suggested to be more prone to develop MetS than lean subjects (33). According to 
IDF diagnostic criteria, 50.75% of subjects with central obesity have MetS in our study. This 
means that, although progression to MetS occurs more frequently in abdominal obese humans 
compared with lean subjects, this association is highly dependent on genetic background (34). 
MetS was defined in 22.82% of participants. The prevalence of MetS in the adult population 
differs depending on the diagnosis criteria and ethnicity, and usually varies between 22 and 
39% (35). Unfortunately, the lack of published data on the MetS prevalence in general 
Croatian population makes the comparison between the investigated young adult populations 
and general population difficult. Adiponectin is the most abundant adipokine in human 
plasma and low levels of adiponectin seem to be associated with poor prognosis (36). The 
data presented in this study support this association. In this study, adiponectin was 
significantly lower in subjects with increased WC and in subjects with developed MetS, 
which is consistent with the claim that hypoadiponectinemia may represent the dysfunction of 
adipose tissue in obesity and is closely associated with the clinical phenotype of MetS (37, 
38). We demonstrated significant correlations between adiponectin plasma concentration and 
clinical (BMI, WC, SBP and DBP) and metabolic variables (HDL-C, TG, GLUC). Other 
authors have also found serum adiponectin levels to be negatively correlated with BMI and 
WC (6) and with adverse features of MetS (11). Because both adiponectin and metabolic 
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variables, as well as blood pressure, were correlated with BMI and WC, and because the 
concentration of adiponectin is sex-dependent, we made the necessary adjustment in analyses 
for BMI, WC and sex, but the correlations between adiponectin, HDL-C, TG, GLUC, SBP 
and DBP were still significant. The results indicate that adiponectin and those variables were 
independent of sex and anthropometric variables (BMI and WC). The present study shows the 
protective/positive influence of adiponectin level on the components of MetS. Some other 
reports have also identified the significant role of adiponectin in the development of MetS and 
of metabolic comorbidities (12), and have suggested that measuring the plasma concentration 
of adiponectin may be a useful biomarker (39). However, regarding the relationship between 
adiponectin and lipid profile indicators, there are still contradicting findings and no general 
consensus has been achieved. We did not find significant correlation between adiponectin and 
LDL-C and TC, which indicates that the effects of adiponection on LDL-C and TC are 
indirect.  While some authors found significant relationship between adiponectin and  lipid 
parameters (40-42), others could not confirm these findings (43). Studies in humans have 
shown that adiponectin decreases body weight by increasing lipid oxidation in muscles and in 
other organs such as the pancreas and liver (44). In this study, a statistically significant 
correlation between SBP, DBP and plasma adiponectin concentration was found, which is in 
agreement with published data on association between decreased plasma adiponectin levels 
and elevated blood pressure (45). Adamczak et al. reported on significantly lower levels of 
adiponectin in patients with essential hypertension compared to normotensive controls (46). 
While the presence of MetS has been linked to decreased adiponectin values, the association 
of ADIPOQ variants with MetS and its components remains vague (15). The effect of the 
ADIPOQ gene on the risk of obesity and MetS may vary according to ethnicity, age and the 
degree of obesity across populations (47). Some studies indicate that ADIPOQ variants may 
contribute to MetS and its components (12,20,36,48) while other reports point to the limited 
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impact of ADIPOQ gene on MetS parameters (15,49). In this study, we found ADIPOQ 
promoter variants -11377C>G and -11391G>A, independently and as haplotypes that are 
associated with elevated blood lipids, central obesity and MetS. Minor -11377G and -11391A 
alleles were associated with central obesity and MetS, with the -11391A variant having shown 
more significant impact. The associations in this study also extend to another feature of the 
MetS, i.e. increased serum concentrations of triglyceride in  -11391A carriers. Also, we found 
a correlation between -11377G-11391A haplotype and a risk of development of MetS, where 
this haplotype also contributes to the highest triglyceride levels. Similar results were obtained 
in other studies in other ethnic groups with regard to associations of rare -11377G (9,18,36, 
47,50), or -11391G>A (51) allele/genotype/haplotype carriers with obesity and obesity-
related phenotypes. In contrast, some other studies demonstrated that the common -11377C 
allele was strongly associated with obesity and MetS parameters (17,52). Our findings are 
also consistent with previous reports in different populations and different age groups 
(53,54,55) stating that  ADIPOQ gene may play an important role in MetS. Results of these 
reports pointed that regional differences in body fat affected the risk of metabolic 
abnormalities, and also ADIPOQ gene variants were suggested as modulators of visceral fat 
accumulation. Identification of genes controlling adiponectin levels may aid our 
understanding of how genes influence MetS and possibly obesity (56). Many study results 
were published on associations of ADIPOQ SNPs (27,36,57) as well as haplotypes with 
plasma adiponectin concentrations (22, 54), but the data are controversial. Association 
between serum adiponectin level and ADIPOQ variants represents one of the several 
mechanisms that can be considered as a link between ADIPOQ and MetS. Other mechanisms 
that could explain the ADIPOQ-MetS association are: insulin resistance, WC, body fat 
distribution, lipid profile. Although the molecular mechanisms underlying the pathogenesis of 
MetS are still far from being fully understood, insulin resistance is in general considered to be 
18 
 
the core defect of MetS (58). The association of plasma adiponectin and insulin sensivity was 
also determined in humans, and lower plasma adiponectin levels were found in more insulin 
resistant subjects (21). 
No significant associations were found between plasma adiponectin values and selected 
ADIPOQ SNPs in this study. The reasons for this may be the following : i) limited number of 
subjects, ii) we measured total adiponectin and did not separate the trimere and hexamere 
structure of adiponectin, limiting the clinical interpretation because recent evidence has 
suggested that the high-molecular-weight adiponectin may be more strongly related to several 
characteristics of the metabolic syndrome complex (59) iii) we analyzed only two promoter 
SNPs while for some other ADIPOQ SNPs have also been reported to be independently 
associated with serum adiponectin. Interactions with other genes related to susceptibility to 
obesity and MetS could have interfered. Various studies reported a multitude of loci identified 
in different chromosomes, varying across populations and reflecting substantial complexity of 
the metabolic syndrome etiology (60-63). 
Potential limitations of our study should be mentioned: 
A rather low number of subjects was included. The effects of environmental factors, 
controlling the risk of obesity and MetS, were not evaluated in this study. The effects of the 
candidate gene markers could be validly evaluated after controlling for environmental factors 
(e.g. physical activity, diet, smoking) and ethnicity (6, 55). Finally, the answer to the question 
of whether or not the findings from this study can be generalized to Croatian population 
remains uncertain because analysis was performed in a rather small group. 
In spite of these limitations, the data obtained suggest that analysis of adiponectin 
concentrations and  -11391G>A and -11377C>G ADIPOQ gene promoter variants could 
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provide information that could be clinically meaningful for estimation of the risk of metabolic 
syndrome and its traits in young adult population. This points to the need of personalized 
behavioral recommendations for prevention of chronic disorders. 
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Table 1. Clinical features of study participants 
 All subjects  Without MetS     With MetS  p-value 
n 
*BMI (kg/m
2
)  
149 
24.17±5.03 
115 
23.04±3.72 
34 
30.29 ±4.69 
 
<0.001 
  WC (cm)  88.14±15.6 82.4±11.5 107.3±11.9 <0.001 
*TG (mmol/L)  1.05±1.01 0.95±0.54 1.88±1.32 <0.001 
  TC (mmol/L)  4.67±1.08 4.53±0.96 5.13±1.32 0.008 
  HDL-C (mmol/L)  1.42±0.34 1.50±0.32 1.13±0.20 <0.001 
*LDL-C (mmol/L)  2.69±0.93 2.40±0.85 3.00±1.06 0.004 
*GLUC (mmol/L)  5.06±0.59 5.00±0.43 5.30±0.85 <0.001 
*DBP (mmHg) 80.0±10.9 80.0±8.3 87.5±14.3 <0.001 
*SBP (mmHg) 120.0±17.79 120.0±10.7 138.5±17.5 <0.001 
*Adiponectin (mg/L) 9.0±7.74 12.36±7.84 4.77±2.09 <0.001 
 
 BMI, body mass index; WC, waist circumference; TG, triglycerides, TC, total cholesterol; 
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; 
GLUC, glucose; DBP, diastolic blood pressure; SBP, systolic blood pressure. 
Data are expressed as mean or *median ± standard deviation (SD) depending on parametric or 
nonparametric distribution. 
Differences between groups were evaluated by Student’s t-test or Mann-Whitney test, 
depending on distribution normality. 
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Table 2. Spearman Rank Correlations Coefficients of the adiponectin with different clinical 
parameters in the whole subject group (n = 149) 
Parameter Correlation 
coefficient (r) 
 95 % CI for r p-value 
BMI (kg/m2)  -0.434 -0.561 to -0.288 <0.001 
WC (cm)  -0.467 -0.616 to -0.361 <0.001 
TG (mmol/L)  -0.499 -0.517 to -0.231 <0.001 
TC (mmol/L)  -0.031 -0.197 to 0.137 0.718 
HDL-C (mmol/L)    0.540   0.410 to 0.649 <0.001 
LDL-C (mmol/L)  -0.131 -0.292 to -0.037 0.124 
GLUC (mmol/L)  -0.214 -0.368 to -0.485 0.012 
DBP (mmHg) -0.387 -0.523 to -0.233 <0.001 
SBP (mmHg) -0.346 -0.487 to -0.187 <0.001 
 
BMI, body mass index; WC, waist circumference; TG, triglycerides, TC, total cholesterol; 
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; 
GLUC, glucose; DBP, diastolic blood pressure; SBP, systolic blood pressure. 
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Table 3. Distribution of the -11377C>G and -11391G>A ADIPOQ genotypes and alleles in 
subjects without (WC< 94 cm (M); WC< 80 cm (F); control) and with (WC≥ 94 cm (M); 
WC≥ 80 cm (F)) central obesity. 
Genotype 
/allele 
Control 
(n=81) 
Central 
obesity 
(n=68)  
OR (95% CI), p aSpecific p p 
-11377C>G  
              CC  
              CG 
             GG  
n (%) 
41 (50.6) 
37 (45.7) 
3 (3.7) 
n (%) 
27 (39.7) 
30 (44.1) 
11 (16.2) 
 
1 (1-1) 
1.23 (0.62-2.44), 0.551  
5.57 (1.42-21.82), 0.014 
 
χ2=1.84,  p=0.175 
χ2=0.04,  p=0.846 
χ2=8.98,  p=0.003 
 
χ2=7.36;  
df=2 
p=0.025 
                C  
                G  
119 (73.5) 
43 (26.5) 
84 (61.8) 
52 (38.2) 
1 (1-1) 
1.71 (1.03-2.85), 0.032 
 χ2=4.65; df=1, 
p=0.031 
-11391G>A  
             GG  
             GA  
             AA 
n (%) 
59 (72.8) 
21 (25.9) 
1 (1.2) 
n (%) 
30 (44.1) 
36 (52.9) 
2 (2.9) 
 
1 (1-1) 
3.37 (1.68-6.75), <0.001 
3.93 (0.34-45.15), 0.271  
 
χ2=12.59, p<0.001 
χ2=11.42, p<0.001 
χ2=0.61, p=0.436 
 
χ2= 12.82; 
 df=2 
p=0.002 
                G  
                A  
 139 (85.8) 
23 (14.2) 
96 (70.6) 
40 (29.4) 
1 (1-1) 
2.52 (1.34-4.72), 0.002 
 χ2=10.29;df=1, 
p=0.001 
 
WC, waist circumference; M, male and F, female; OR, odds ratio  
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aSpecific p = individual vs. other genotypes 
Comparisons of subject groups were performed using χ2 test or Fisher’s exact test. 
Table 4. Distribution of the -11377C>G and -11391G>A ADIPOQ genotypes and alleles in 
subjects without (TG<1.695 mmol/L) and with (TG≥1.695mmol/L) hypertriglyceridemia  
Genotype 
/allele 
TG < 1.695 mmol/L 
(n=117) 
TG > 1.695 mmol/L 
(n=32) 
p 
-11377C>G  
                CC 
               CG 
               GG 
n (%) 
58 (49.6) 
50 (42.7) 
9 (7.7) 
n (%) 
10 (31.3) 
17 (53.1) 
5 (15.6) 
 
χ
2=4.084;df=2 
p=0.130 
C 
G 
166 (70.9) 
68 (29.1)  
37 (57.8) 
27 (42.2) 
χ
2=3.988; df=1 
p=0.046 
-11391G>A 
               GG 
GA 
AA 
n (%) 
75 (64.1) 
41 (35.0) 
1 (0.9) 
n (%) 
14 (43.8) 
16 (50.0) 
2 (6.3) 
 
χ
2=6.069; df=2 
p=0.048 
G 
A 
191 (81.6) 
43 (18.4) 
44 (68.8) 
 20 (31.2) 
χ
2=4.996; df=1 
p= 0.025 
 
TG, triglycerides;  
Comparisons of subject groups were performed using χ2 test or Fisher’s exact test. 
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Table 5. Distributions of the -11377C>G and -11391G>A ADIPOQ genotypes in the group of 
subjects with and without MetS 
Genotype/ 
allele 
Control 
(n=115) 
MetS 
(n=34) 
OR (95% CI), p aSpec.p p 
-11377C>G 
              CC 
             CG 
             GG 
n (%) 
59 (51.3) 
47 (40.9) 
9 (7.8) 
n (%) 
9 (26.5) 
20 (58.8) 
5 (14.7) 
 
1 (1-1) 
2.79 (1.16-6.69), 0.013 
3.64 (0.99-13.35), 0.052 
 
χ
2=6.87, p=0.009 
χ
2=3.35, p=0.067 
χ
2
=1.14, p=0.285 
 
χ
2 = 6.96;df=2 
p=0.031 
                 C 
                G 
165 (71.7) 
65 (28.2) 
38 (55.9) 
30 (44.1) 
1 (1-1) 
2.00 (1.093.67), 0.015 
 
 
χ
2 = 5.86;df=1 
p=0.015 
-11391G>A 
             GG 
             GA 
             AA 
n (%) 
76 (66.1) 
38 (33.0) 
1 (0.9) 
n (%) 
13 (38.2) 
19 (55.9) 
2 (5.9) 
 
1 (1-1) 
2.92 (1.31-6.54), 0.009 
11.69 (0.99-138.4), 0.051 
 
χ
2=7.72, p=0.005 
χ
2=5.29, p=0.021 
χ
2=2.62, p=0.106 
 
χ
2
=9.65; df=2 
p=0.008 
 
               G 
               A 
190 (82.6) 
40 (17.4) 
45 (66.2) 
23 (33.8) 
1 (1-1) 
2.43 (1.22-4.83), 0.004 
 χ2=7.87; df=2 
p=0.005 
 
MetS, metabolic syndrome; OR, odds ratio 
aSpecific. p = individual vs. other genotypes 
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Comparisons of subject groups were performed using χ2 test or Fisher’s exact test. 
